10 completed, 4 terminated, 4 unknown, 1 withdrawn. 11 Phase 1, 7 Phase 2, 2 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Completed 8, Terminated 3 |
| Phase 2 | 7 | Completed 3, Terminated 2, Unknown 2 |
| Phase 3 | 2 | Unknown 2 |
| Not applicable | 1 | Withdrawn 1 |
Follow advexin: new trials by email Literature Review of advexin trials Research Report on advexin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer Ad-P53, Xeloda, Keytruda - Metastatic Solid Tumor Cancer, Recurrent Head and Neck Cancer | Phase 1 / Phase 2 | Terminated | MultiVir, Inc. | 4 | 2018-11-20 | 2020-06-02 |
| Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors. Ad-p53 - Solid Tumor, Lymphoma | Phase 2 | Unknown | MultiVir, Inc. | 40 | 2018-10-01 | 2020-06-09 |
| C11 AMT Positron Emission Tomography (PET) Imaging in Patients With Metastatic Invasive Breast Cancer Adenovirus-p53 transduced dendritic cell vaccine, 1-methyl-D-tryptophan, Carbon C 11 alpha-methyltryptophan - Breast Cancer | Not applicable | Withdrawn | H. Lee Moffitt Cancer Center and Research Institute | 2013-01-01 | 2017-02-23 | |
| Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx Ad5CMV-p53 gene, laboratory biomarker analysis - Lip and Oral Cavity Cancer, Oropharyngeal Cancer | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 51 | 2003-06-01 | 2013-01-23 |
| Wild Type p53 Adenovirus for Oral Premalignancies INGN 201 - Mouth Cancer | Phase 1 | Terminated | M.D. Anderson Cancer Center | 4 | 2003-06-01 | 2011-12-07 |
| S0011, Gene Therapy & Surgery Followed by Chemo & RT in Newly Diagnosed Cancer of the Mouth or Throat Ad5CMV-p53 gene, cisplatin, conventional surgery - Head and Neck Cancer | Phase 2 | Terminated | SWOG Cancer Research Network | 13 | 2003-02-01 | 2012-06-14 |
| Chemotherapy Combined With Gene Therapy in Treating Patients Who Have Stage III or Stage IV Breast Cancer Ad5CMV-p53 gene, docetaxel, doxorubicin hydrochloride - Breast Cancer | Phase 2 | Completed | Introgen Therapeutics | 2002-02-01 | 2013-05-30 | |
| Gene Therapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer Ad5CMV-p53 gene, radiation therapy - Lung Cancer | Phase 1 | Completed | Eastern Cooperative Oncology Group | 2000-01-01 | 2010-07-07 | |
| Gene Therapy in Treating Patients With Recurrent Malignant Gliomas Ad5CMV-p53 gene, conventional surgery - Brain and Central Nervous System Tumors | Phase 1 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 1999-02-25 | 2018-06-27 | |
| Gene Therapy Plus Chemotherapy in Treating Patients With Breast Cancer Ad5CMV-p53 gene, chemotherapy - Breast Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 20 | 1999-01-01 | 2013-02-07 |
| Gene Therapy in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Surgically Removed Ad5CMV-p53 gene - Lung Cancer | Phase 1 | Completed | Eastern Cooperative Oncology Group | 1998-11-17 | 2023-06-22 | |
| Gene Therapy in Treating Patients With Advanced Recurrent or Persistent Ovarian Cancer or Primary Peritoneal Cancer Ad5CMV-p53 gene - Ovarian Cancer, Peritoneal Cavity Cancer | Phase 1 | Completed | University of Texas Southwestern Medical Center | 1998-09-01 | 2021-02-02 | |
| Gene Therapy in Treating Patients With Ovarian Cancer Ad5CMV-p53 gene, laparoscopic surgery - Ovarian Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 1998-09-01 | 2013-02-08 |
| Gene Therapy in Treating Patients With Advanced Bladder Cancer Ad5CMV-p53 gene - Recurrent Bladder Cancer, Stage I Bladder Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 24 | 1998-05-01 | 2013-01-23 |
| Gene Therapy in Treating Patients With Cancer of The Liver Ad5CMV-p53 gene - Liver Cancer | Phase 1 | Terminated | National Cancer Institute (NCI) | 30 | 1998-02-01 | 2013-02-05 |
| Gene Therapy in Treating Patients With Recurrent Head and Neck Cancer Ad5CMV-p53 gene - Head and Neck Cancer | Phase 2 | Unknown | Aventis Pharmaceuticals | 39 | 1998-01-01 | 2013-12-04 |
| Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone INGN 201 - Carcinoma, Squamous Cell | Phase 3 | Unknown | Introgen Therapeutics | 2007-09-11 | ||
| Study to Determine the Efficacy and Safety of Docetaxel and Doxorubicin With INGN 201 in Locally Advanced Breast Cancer INGN 201 - Locally Advanced Breast Cancer (LABC) | Phase 2 | Completed | Introgen Therapeutics | 60 | 2008-04-01 | |
| Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate INGN 201 - Carcinoma, Squamous Cell | Phase 3 | Unknown | Introgen Therapeutics | 2008-04-01 |
Squamous Cell Carcinoma of Head and Neck (4) · Breast Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (3) · Head and Neck Neoplasms (3) · Carcinoma, Ovarian Epithelial (2) · Carcinoma, Squamous Cell (2) · Liver Neoplasms (2) · Lung Neoplasms (2) · Mouth Neoplasms (2) · Neoplasm Metastasis (2) · Ovarian Neoplasms (2) · Adenocarcinoma, Bronchiolo-Alveolar (1) · Astrocytoma (1) · Brain Neoplasms (1) · Breast Neoplasms, Male (1)
National Cancer Institute (NCI) (5) · Introgen Therapeutics (4) · Eastern Cooperative Oncology Group (2) · MultiVir, Inc. (2) · Aventis Pharmaceuticals (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · M.D. Anderson Cancer Center (1) · SWOG Cancer Research Network (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · University of Texas Southwestern Medical Center (1)
United States (18)
Julie L Sicam, MT (ASCP) MSHS (2) · Kerstin Menander, MD (2) · Carolyn Y. Muller, MD (1) · Chandra P. Belani, MD (1) · David P. Carbone, MD, PhD (1) · Frederick F. Lang, MD (1) · Gary L. Clayman (1) · Gary L. Clayman, MD (1) · George H. Yoo, MD (1) · Hatem Soliman, M.D. (1) · Jill Van Warthood, PhD (1) · Joan H. Schiller, MD (1) · Judith K. Wolf, MD (1) · Lance Pagliaro (1) · Lyndah Dreiling, MD (1)
P50CA097007 (1), R21CA076233 (1), U10CA032102 (1)